Traynor Capital Management Inc. Takes Position in Exelixis, Inc. (EXEL)
Traynor Capital Management Inc. acquired a new position in Exelixis, Inc. (NASDAQ:EXEL) during the second quarter, according to its most recent disclosure with the SEC. The fund acquired 10,150 shares of the biotechnology company’s stock, valued at approximately $275,000.
Other hedge funds also recently bought and sold shares of the company. Fortaleza Asset Management Inc. bought a new stake in Exelixis during the first quarter worth approximately $106,000. First Quadrant L P CA bought a new stake in Exelixis during the second quarter worth approximately $144,000. Meeder Asset Management Inc. bought a new stake in Exelixis during the first quarter worth approximately $170,000. Wetherby Asset Management Inc. bought a new stake in Exelixis during the second quarter worth approximately $218,000. Finally, Capstone Asset Management Co. bought a new stake in Exelixis during the second quarter worth approximately $242,000. Hedge funds and other institutional investors own 80.19% of the company’s stock.
Shares of Exelixis, Inc. (NASDAQ EXEL) opened at 26.51 on Friday. The firm has a 50-day moving average price of $26.12 and a 200 day moving average price of $22.29. The stock has a market cap of $7.79 billion, a PE ratio of 133.89 and a beta of 1.89. Exelixis, Inc. has a 12-month low of $10.04 and a 12-month high of $28.45.
Exelixis (NASDAQ:EXEL) last announced its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.02. The firm had revenue of $99.01 million during the quarter, compared to the consensus estimate of $85.27 million. Exelixis had a return on equity of 80.43% and a net margin of 18.20%. The business’s revenue for the quarter was up 173.1% on a year-over-year basis. During the same period in the prior year, the business earned ($0.15) EPS. Equities research analysts predict that Exelixis, Inc. will post $0.26 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Traynor Capital Management Inc. Takes Position in Exelixis, Inc. (EXEL)” was first reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this report on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The correct version of this report can be accessed at https://theolympiareport.com/2017/08/12/traynor-capital-management-inc-takes-position-in-exelixis-inc-exel.html.
A number of analysts recently commented on the company. Piper Jaffray Companies reiterated a “buy” rating and set a $29.00 price objective on shares of Exelixis in a research report on Thursday, August 3rd. William Blair reiterated an “outperform” rating on shares of Exelixis in a research report on Thursday, July 27th. TheStreet upgraded Exelixis from a “c” rating to a “b-” rating in a research report on Monday, August 7th. Cowen and Company reiterated an “outperform” rating on shares of Exelixis in a research report on Thursday. Finally, Oppenheimer Holdings, Inc. initiated coverage on Exelixis in a research report on Monday, June 12th. They set a “hold” rating for the company. Five investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Exelixis presently has a consensus rating of “Buy” and a consensus target price of $25.57.
In related news, Director Carl B. Feldbaum sold 32,988 shares of the stock in a transaction dated Monday, May 15th. The stock was sold at an average price of $21.58, for a total value of $711,881.04. Following the completion of the sale, the director now directly owns 52,721 shares of the company’s stock, valued at approximately $1,137,719.18. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Patrick J. Haley sold 5,000 shares of the stock in a transaction dated Tuesday, May 30th. The stock was sold at an average price of $18.46, for a total value of $92,300.00. The disclosure for this sale can be found here. 5.10% of the stock is currently owned by corporate insiders.
Exelixis Company Profile
Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.
Receive News & Ratings for Exelixis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.